August 2015 Newsletter
16th World Conference on Lung Cancer is a Few Days Away - The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries to discuss the latest developments in thoracic malignancy research. Attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses, allied health professionals, advocates and patients. View Details
Fun Walk – Pancake Breakfast at the World Conference on Lung Cancer
Kool & The Gang to Headline WCLC 2015 Gala Dinner
GAIN Programs - United States Locations
Multidisciplinary Hands-On Live Learning: Molecular Testing and Personalized Therapy in Lung Cancer
4th AACR-IASLC International Joint Conference on Lung Cancer Translational Science: From the Bench to the Clinic
16th Annual Targeted Therapies of Lung Cancer Meeting
European Lung Cancer Conference 2016
Asia Pacific Lung Cancer Conference 2016
Latin American Lung Cancer Conference 2016
The first is the 2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. (Fourth edition). Featured in a Plenary session on Tuesday, Sept. 8, this reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. It describes diagnostic criteria, pathological features, and associated genetic alterations in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. The book, prepared by 157 authors from 29 countries, contains more than 800 color images and tables, and more than 3,000 references.
The second global initiative from the IASLC is the Revised (8th) Edition of TNM Staging System for Lung Cancer, which will also be discussed at the Plenary session on Tuesday, Sept. 8. 'The recommendations proposed by the IASLC assign more prognostic impact to tumor size, propose the reclassification of some T descriptors, acknowledge the prognostic relevance of quantification of nodal involvement, include more metastatic subgroups and more stages. These changes will help the clinician to better indicate and stratify prognosis, which is one of the main objectives of the TNM classification.
Another significant announcement includes an updated Statement on Tobacco Control and Smoking Cessation. This is the first declaration on tobacco since 2007 and updates our organization’s goals. It also includes worldwide recommendations from IASLC to governments so they can better assist in eliminating lung cancer around the globe.
New Publisher for JTO
Beginning January 2016, Elsevier will be the new publisher of the Journal of Thoracic Oncology (JTO). The partnership with Elsevier allows the JTO to continue its growth while providing enhanced features for authors and readers. The change provides researchers with increased access to cutting-edge research through Elsevier’s various portals. Individual authors will have opportunities for seamless and easy dissemination of their important work.
JTO joins Elsevier’s extensive catalog of leading cancer journals. The Editor-in-Chief, Alex A. Adjei, MD, PhD, is working closely with publisher, Mary Heffner, to maximize the benefits that Elsevier can provide for authors and readers of JTO. The Managing Editor, Mary Sharkey Todd, continues to provide support and guidance to the JTO and IASLC community. You can reach the Editorial Office via email through Mary.Todd@iaslc.org.
As we look to the future, we must also take a moment to reflect on the JTO’s first 10 years. The hard work and dedication of the staff at Lippincott Williams & Wilkins, especially our publisher, David Myers, and our production editor, Jennifer Sollenberger, is gratefully acknowledged. Their efforts were critical to the success of our journal.
On July 31, Dr. Fred R. Hirsch, CEO of IASLC, Professor of Medicine and Pathology at the University of Colorado, received the Bonnie J. Addario Lung Cancer Foundation award for his leadership, excellence in practice and research to improve lung cancer treatment. Bonnie J. Addario presented him with the 2015 Addario Lectureship Award at the 16th Annual International Lung Cancer Congress (ILCC) in Huntington Beach, Calif. View Details.
Yale Cancer Center Receives $11 Million from National Cancer Institute for Lung Cancer Research
Armed with an $11 million grant from the National Cancer Institute (NCI), the Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, Conn. will launch a new research program in non-small cell lung cancer, one of the world’s most prevalent and lethal forms of cancer.
“The only way to approach a problem as big as lung cancer is to have experts in basic, translational, and clinical research working on several fronts taking the research from the lab to the clinic and back again to develop even newer insights,” said principal investigator Roy S. Herbst, M.D., the Ensign Professor of Medicine, chief of the Medical Oncology Program at Smilow Cancer Hospital at Yale-New Haven, and associate director for the Translational Research Program at Yale Cancer Center. “This effort represents tremendous teamwork by investigators to combat this very common and all-too-fatal disease.”
September 2015: The International Association for the Study of Lung Cancer (IASLC) and the Journal of Thoracic Oncology (JTO) are pleased to present this feature each month to highlight certain articles of interest. The selected articles each month will be made available to the public for a limited time at the time of print. The articles below from the August issue of JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
The World Health Organization (WHO) Classification of Tumors is a global standard for tumor diagnosis. To make these classifications current and relevant to the state of the science, they are periodically updated. The 2015 WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published. Based on the leadership role taken by the IASLC pathology committee in this work, this journal will be publishing a series of articles summarizing key points about the new classification, and outlining the major changes from the 2004 classification. This the first in the series.
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study
Vansteenkiste et al. describe a phase II study which brings up the complex issue of actionable mutations. The study demonstrates modest activity of the PI3-Kinase inhibitor, buparlisib in NSCLC even after selection for PIK3CA mutations, suggesting that these mutations are not classical drivers.
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial
This is a phase III study of preoperative and perioperative chemotherapy for resectable squamous cell carcinoma of the esophagus.
Role of Postoperative Radiotherapy in Nonlocalized Thymoma: Propensity-Matched Analysis of Surveillance, Epidemiology, and End Results Database
Kim and colleagues utilize the SEER database to provide data on the post-operative radiation in resected non-localized thymoma.
Khaled Alkattan, FRCS
The Gulf States and Arabic regions have a rapid growth in membership but the number of members remains small. According to the Global Lung Cancer Coalition, the number of lung cancer cased diagnosed in 2012 was 824 in Saudia Arabia; the number of lung cancer deaths reached 734 in 2012. A cancer plan in operation started in 2010, as well as a cancer registry.
The Saudi Thoracic Society (STS) is a non-profit, professional and scientific society for respiratory and critical care medicine. They are committed to the prevention and treatment of respiratory disease through research, education, patient care. In keeping with these goals, the Saudi Thoracic Society interacts with both national and international organizations which have similar goals. This year the STS hosted the Thoracic Oncology Forum 2015 on April 9 to 11.
MEMBERS! Visit the IASLC Booth at WCLC 2015
Invite your colleagues to join (see details below), and you will be entered into a drawing for a free iPad, to be awarded at the WCLC 2015. New Members joining IASLC for the first time can take advantage of 2-years for the price of 1-year Membership if they sign up at the WCLC 2015. Definitely encourage any Fellows/Students/Trainees to join for free!
Thanks for your membership in IASLC and your support in growing our global team! Invite a Colleague Now
COMPLIMENTARY Fellows/Residents/Students/Trainees Membership – Group Program Registration
WCLC 2015: Free Attendance for Patients/Survivors!
Over this life changing weekend, survivors, patients, caregivers, advocates and healthcare professionals will learn how to bring the lung cancer movement to their communities. This year’s Summit is being held in the gorgeous NYC Metro Area from 9/17-9/20. The three days of interactive training sessions will teach you how to inspire change, educate others, and boost your advocacy impact! Learn More
12th International Conference of Asian Clinical Oncology Society (ACOS)
Many cancers are preventable, many are curable and rest are treatable. Asia is the largest continent, houses 60% of world population and has major cancer burden. Asian countries share challenges in terms of cancer types, therefore there is a greater need to collaborate and address the gaps to have better cure and care of cancer patients. Therefore the theme of conference is “Cancer in Asia: Bridging the Gaps”.
The objectives of ACOS includes cancer prevention, epidemiology, statistics, multidisciplinary treatment i.e. surgery, chemotherapy including oriental medicine, radiotherapy, as well as patient care under high grade development of translational research.
The ACOS is the Biennial International Conference, held in one of our various member countries in Asia. Our aim is foster cancer research & treatment in Asia, clinical experience sharing and enhancing professional networks resulting in advancements of data collation and publication to address the needs of oncologists and cancer patients in Asia. Details
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
February 20 - 23 2019Santa Monica, California
April 3 - 5 2019New York, New York
April 10 - 13 2019Geneva, Switzerland